NCT04356859
The Acute Burn ResUscitation Multicenter Prospective Trial
- Katrina Falwell, RN, BSN - Role: CONTACT - Phone: 916-453-2134 - Email: kafalwell@ucdavis.edu
- Mary Beth Lawless, RN, MS - Role: CONTACT - Phone: 916-453-2132 - Email: mblawless@ucdavis.edu
NA
RECRUITING
NCT04356859
INTERVENTIONAL
The Acute Burn ResUscitation Multicenter Prospective Trial (ABRUPT2)
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Inclusion Criteria:
* Age ≥ 18 years
* Total burn size (second and third degree) is ≥ 25% of the TBSA
* Burn center admission within 12 hours of injury.
* There is a plan for formal fluid resuscitation.
Exclusion Criteria:
* Significant associated trauma
* High voltage (≥ 1000 volts) electrical burns
* Burn wound excision surgery within 48 hours from injury
* Fresh frozen plasma (FFP) given at any time ≤ 48 hours from injury
* Hypertonic saline (HTS) given at any time ≤ 48 hours from injury
* Hydroxyethyl starch (HES) given at any time ≤ 48 hours from injury
* High dose Vitamin C infusion given at any time ≤ 48 hours from injury
* Administration of human albumin prior to randomization
* Palliative comfort measures are instituted ≤ 48 hours from injury
* Pregnancy
* Pre-injury chronic renal insufficiency equal to or greater than stage 3
* Pre-injury chronic hepatic disease (Child-Pugh B or C)
* Pre-injury left ventricular (LV) dysfunction (echocardiography LV grade II-IV or ejection fraction ≤ 35%)
Burn Injury
- TREATMENT
-
- Type: DRUG
- Name: Albumin Human
- Description: Addition of albumin during acute resuscitation following burn injury
- Arm Group Labels: Colloid
- American Burn Association